| Epidemiology Prevalence and Incidence in Dry-Form (Non-Neovascular) Age Related Macular Degeneration | Turgut YILMAZ | 97–99 |
| Genetic and Risk factors in Dry-Form (Non-Neovascular) Age Related Macular Degeneration | Yüksel SÜLLÜ | 100–104 |
| Classification and Pathogenesis in Dry-Form (Non-Neovascular) Age Related Macular Degeneration | Özcan KAYIKÇIOĞLU | 105–111 |
| Macular Pigments | YUSUF AKAR,M. Kazım EROL | 112–115 |
| Drusen Types and Imaging Characteristics | Mümin HOCAOĞLU,Serra ARF,Murat KARAÇORLU | 116–123 |
| Geographic Atrophy: Clinical Features and Diagnosis | Nurten ÜNLÜ,Gözde AKSOY AYDEMİR | 124–127 |
| Follow-up in Dry-Form (Non-Neovascular) Age Related Macular Degeneration and Change to Wet Type | MUHAMMED BATUR,SEREK TEKİN,ERBİL SEVEN | 128–134 |
| Nutritional Therapy in Dry-form (Non-Neovascular) Age Related Macular Degeneration | MEHMET ÇITIRIK,Çağrı İLHAN,MEHMET YASİN TEKE | 135–144 |
| Non-Nutritional Medical Treatments in Dry-Form (Non-Neovascular) Age Related Macular Degeneration | METE GÜLER,Fatih Cem GÜL,Murat KAYA | 145–148 |
| Gene therapy, Stem Cell Treatment and Retinal Implant in Dry-Form (Non-Neovascular) Age Related Macular Degeneration | Uğur ACAR | 149–154 |
| Classical, Micropulse and NanoSecond Laser Therapy in Dry-Form (Non-Neovascular) Age Related Macular Degeneration | Tolga BİÇER,MEHMET ÇITIRIK | 155–159 |